Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bmj.n465 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Parent Perspectives on Nirsevimab for Their Newborn.
Pediatrics
December 2024
Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut.
Article Synopsis
- In 2023, nirsevimab was approved in the U.S. as a monoclonal antibody to prevent bronchiolitis in newborns caused by RSV, prompting a study on parental responses to this recommendation.
- A study involving 28 parents revealed that 38% planned to administer nirsevimab, 25% opted out, and the remaining were uncertain, highlighting significant knowledge gaps about RSV and the treatment.
- Key concerns for parents included trust in pediatricians, fear of side effects, and misinformation likening nirsevimab to the COVID-19 vaccine, suggesting the need for improved awareness and communication among healthcare providers and parents.
Aim: Examine the trends and epidemiological features of acute hospitalized bronchiolitis cases among children aged 28 days to 2 years, both before and after the COVID-19 pandemic. Furthermore, evaluate their need for intensive care unit (ICU) admission and identify primary risk factors associated with severe bronchiolitis.
Methods: A retrospective analysis was conducted on the medical records of paediatric patients admitted to Meyer Children's Hospital in Florence (Italy) from September 2019 to March 2023, with the diagnosis of bronchiolitis.
Impact of Bacille Calmette-Guérin vaccination on the therapeutic schedule of infantile epileptic spasms syndrome: A 25-year Japanese single-center survey.
Vaccine X
October 2024
Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
Adrenocorticotropic hormone (ACTH) therapy is effective for infantile epileptic spasms syndrome (IESS) but can induce immunosuppression. In Japan, Bacille Calmette-Guérin (BCG) vaccination, modified in 2013 to reduce osteitis/osteomyelitis risk, coincides with the peak onset age of IESS. This raises concerns about infection risks when administering ACTH therapy post-vaccination.
View Article and Find Full Text PDFThe Role of the Basophil Activation Test in the Diagnosis of Drug-Induced Anaphylaxis.
Diagnostics (Basel)
September 2024
Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Botaniczna St. 3, 31-501 Krakow, Poland.
The diagnosis of drug-induced anaphylaxis (DIA) is a serious health problem. The Basophil activation test (BAT) is considered a specific in vitro provocation, and compared to in vivo provocation, it is more convenient, cheaper, and safer for the patient. This study aimed to evaluate the usefulness of the BAT in the diagnosis of DIA.
View Article and Find Full Text PDFShort-Term Immunogenicity of Licensed Subunit RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) Compared to Community-Dwelling Older Adults.
J Am Med Dir Assoc
November 2024
Division of Infectious Diseases, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Objectives: Phase 3 licensing trials for the recently approved respiratory syncytial virus (RSV) vaccines did not include many residents of long-term care facilities (LTCF). Our primary objective was to assess humoral immune responses in LTCF residents, aged 60 and older, to the RSV vaccines, and demonstrate noninferiority to antibody responses in community-dwelling (CD) adults who were representative of the phase 3 trial participants in whom the vaccines were highly efficacious.
Design: Prospective non-randomized intervention trial of RSV vaccines in LTCF residents.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!